Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common.
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis […]
Background Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma.
(UroToday.com) Following the proffered paper presentation from Dr. Nicholas James of the long-term data assessing abiraterone acetate in patients with hormone-sensitive metastatic prostate cancer, Dr. Maria De Santis discussed the accumulating data and experience in the treatment of metastatic naïve/sensitive prostate cancer.
San Francisco, CA (UroToday.com) — An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.
(UroToday.com) There is a need to identify biomarkers to guide initial treatment decisions and monitor treatment response among patients undergoing systemic therapy for metastatic renal cell carcinoma (mRCC). Assessment of circulating cell-free tumor DNA (ctDNA) is a non-invasive approach to assess tumor-level genetic alterations. Previously, it has been shown that ctDNA profiles evolve along with […]
(UroToday.com) Following the proffered paper presentations from Dr. Maxime Meylan and Dr. Zeynep Zengin looking at predictive markers in advanced kidney cancer, Dr. Walter Berger provided an invited discussion of these data. He began by highlighting the current circumstances of precision therapy in renal cell carcinoma – despite tremendous benefits from targeted therapy and immune checkpoint […]
(UroToday.com) The CARD trial, presented at ESMO 2019, demonstrated a benefit with cabazitaxel chemotherapy with regards to radiographic progression-free survival and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed within 12-months of starting anti-androgen therapy with either enzalutamide or abiraterone. The presence of mutations in DNA-damage repair genes has been found in up […]
(UroToday.com) The NIVOREN GETUG-AFU 26 is a phase II multicenter prospective cohort study aimed at assessing the safety and efficacy of nivolumab among patients with metastatic renal cell carcinoma (mRCC) following the progression of one or two tyrosine kinase inhibitors in a “real world” setting. The results of this trial were reported at the 2019 ASCO […]
(UroToday.com) While multiple new therapies have been shown to prolong overall survival in metastatic castration-resistant prostate cancer (mCRPC), resistance inevitably develops. In this presentation, Dr. Markowski presents results from a phase 1b/2 study of a novel tubulin inhibitor called VERU-111 in men with mCRPC who failed prior therapy with an anti-androgen.
